Please use this identifier to cite or link to this item:
|Title:||The population attributable fraction as a measure of the impact of warfarin pharmacogenetic testing|
population attributable fraction
|Source:||Chan, S.L., Suo, C., Chia, K.S., Teo, Y.Y. (2012-08). The population attributable fraction as a measure of the impact of warfarin pharmacogenetic testing. Pharmacogenomics 13 (11) : 1247-1256. ScholarBank@NUS Repository. https://doi.org/10.2217/pgs.12.104|
|Abstract:||Aim: We aimed to estimate the population impact of warfarin pharmacogenetic testing (WPGT) across multiple populations. Materials & methods: We used the expanded International Warfarin Pharmacogenetics Consortium data set and genotype frequencies from HapMap to simulate dose distributions for each CYP2C9/VKORC1 genotype combination in the different races, and calculated the population attributable fraction as a measure of population impact of WPGT. WPGT was compared to both clinical and fixed-dose algorithms to estimate the benefits of WPGT. Results: Our dose simulation revealed different dose requirements in difference races and considerable overlap in dose distributions of different genotype combinations. Population attributable fraction calculations suggest that complete implementation of WPGT can reduce inaccurate dosing by 18-24% in white individuals. However black, Japanese and Chinese patients do not benefit from WPGT, especially when compared against a race-specific fixed dose. Conclusion: Our findings support WPGT in white individuals but not in black, Japanese and Chinese individuals. Original submitted 28 March 2012; Revision submitted 11 June 201. © 2012 Future Medicine Ltd.|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Feb 28, 2018
WEB OF SCIENCETM
checked on Feb 19, 2018
checked on Mar 12, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.